通化金马药业集团股份有限公司2025年第三季度报告

Core Viewpoint - The company, Tonghua Jinma Pharmaceutical Group Co., Ltd., has disclosed its third-quarter financial report for 2025, ensuring the accuracy and completeness of the information provided [2][7]. Financial Data - The third-quarter financial report has not been audited [6]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - There are no non-recurring profit and loss items applicable for the reporting period [3]. Shareholder Information - The report includes details on the total number of common shareholders and the top ten shareholders, but there are no changes in the shareholding structure due to securities lending activities [5]. Board Meeting - The 11th meeting of the 11th Board of Directors was held on October 24, 2025, with all nine directors present [8][9]. - The meeting was chaired by Zhang Yufu, and it complied with relevant laws and regulations [10][11]. - The board unanimously approved the third-quarter report during the meeting [12][14].